Evaluation of mortality attributable to SARS-CoV-2 vaccine administration using national level data from Qatar.

Autor: Butt AA; Corporate Quality and Patient Safety Department, Hamad Medical Corporation, Doha, Qatar. aabutt@hamad.qa.; Department of Medicine, Weill Cornell Medicine, New York, NY, USA. aabutt@hamad.qa.; Department of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA. aabutt@hamad.qa.; Department of Medicine, Weill Cornell Medicine, Doha, Qatar. aabutt@hamad.qa.; Department of Population Health Sciences, Weill Cornell Medicine, Doha, Qatar. aabutt@hamad.qa., Guerrero MD; Corporate Quality and Patient Safety Department, Hamad Medical Corporation, Doha, Qatar., Canlas EB; Corporate Quality and Patient Safety Department, Hamad Medical Corporation, Doha, Qatar., Al-Dwairi H; Corporate Quality and Patient Safety Department, Hamad Medical Corporation, Doha, Qatar., Alimam ABMA; Communicable Diseases Center, Hamad Medical Corporation, Doha, Qatar., Mohamad AR; Communicable Diseases Center, Hamad Medical Corporation, Doha, Qatar., Ali MT; Heart Hospital, Hamad Medical Corporation, Doha, Qatar., Asaad NA; Heart Hospital, Hamad Medical Corporation, Doha, Qatar., Alkeldi AASS; Corporate Quality and Patient Safety Department, Hamad Medical Corporation, Doha, Qatar., Mohammad MFS; Corporate Quality and Patient Safety Department, Hamad Medical Corporation, Doha, Qatar., Thomas AG; Corporate Quality and Patient Safety Department, Hamad Medical Corporation, Doha, Qatar., Al-Khal A; Communicable Diseases Center, Hamad Medical Corporation, Doha, Qatar., Al-Maslamani M; Communicable Diseases Center, Hamad Medical Corporation, Doha, Qatar., Abou-Samra AB; Corporate Quality and Patient Safety Department, Hamad Medical Corporation, Doha, Qatar.; Department of Medicine, Weill Cornell Medicine, Doha, Qatar.
Jazyk: angličtina
Zdroj: Nature communications [Nat Commun] 2023 Jan 03; Vol. 14 (1), pp. 24. Date of Electronic Publication: 2023 Jan 03.
DOI: 10.1038/s41467-022-35653-z
Abstrakt: Accurate determination of mortality attributable to SARS-CoV-2 vaccination is critical in allaying concerns about their safety. We reviewed every death in Qatar that occurred within 30 days of any SARS-CoV-2 vaccine administration between January 1, 2021 and June 12, 2022. Probability of association with SARS-CoV-2 vaccination was determined by four independent trained reviewers using a modified WHO algorithm. Among 6,928,359 doses administered, 138 deaths occurred within 30 days of vaccination; eight had a high probability (1.15/1,000,000 doses), 15 had intermediate probability (2.38/1,000,000 doses), and 112 had low probability or no association with vaccination. The death rate among those with high probability of relationship to SARS-CoV-2 vaccination was 0.34/100,000 unique vaccine recipients, while death rate among those with either high or intermediate probability of relationship to SARS-CoV-2 vaccination was 0.98/100,000 unique vaccine recipients. In conclusion, deaths attributable to SARS-CoV-2 vaccination are extremely rare and lower than the overall crude mortality rate in Qatar.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz: